FDA Clears First Targeted Dermatomyositis Treatment From Roivant - Roivant Sciences (NASDAQ:ROIV)

FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.

Raccontata dabenzinga.com